Eisai R&d Management Co., Ltd.

Eisai Inc.

Jiayi Wu

Yimin Jiang

Xiang-Yi Li

Kenichi Nomoto

Sergei I Agoulnik

Jean-Christophe P Harmange

Lynn D Hawkins

Shawn Schiller

Frank Fang

Hong Du

Huiming Zhang

Bruce Decosta

John (Yuan) Wang

Charles W Johannes

Pamela McGuiness

Mary Vermeulen

Sharon McGonigle

Kozo Akasaka

Erin A Murphy

David Cox

Alton Kremer

The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor (e.g., E7449), and, optionally, a platinum-based antineo-plastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a platinum-based antineoplastic drug (e.g., carboplatin).

Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer

The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.

Use of eribulin and lenvatinib as combination therapy for treatment of cancer

The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): 

Multikinase inhibitors for use in the treatment of cancer

The present invention provides compounds having formula (1): wherein R-R, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Eponemycin and epoxomicin analogs and uses thereof

Growing community of inventors

Brookline, MA, United States of America

Jiayi Wu